At a median five-year follow-up, the combination reduced the risk of recurrence or death by 49%. How clinically meaningful is this level of durability in the adjuvant melanoma setting?

The hazard ratio has remained favorable across multiple follow-up analyses. What does this consistency tell us about the underlying biology of the treatment effect?

KEYTRUDA alone already provides substantial benefit in resected melanoma. How should clinicians interpret the added value of individualized neoantigen therapy on top of PD-1 inhibition?

Given the personalized nature of intismeran autogene, are there specific tumor or patient characteristics that may ultimately help identify those most likely to benefit?

Both agents were administered for approximately one year. Do the sustained outcomes raise questions about optimal treatment duration in adjuvant immunotherapy?

The safety profile has remained consistent over time. How important is long-term safety reassurance when introducing a personalized immunotherapy into earlier-stage disease?

With Phase 3 trials underway across multiple tumor types, what endpoints will be most critical to confirm the promise suggested by KEYNOTE-942?

Do these data meaningfully shift expectations for individualized mRNA-based cancer vaccines as part of standard oncology practice?